Fig. 2.
Fig. 2. Estimated radiation absorbed doses per millicurie of131I administered for (A) all patients, (B) patients with AML or MDS, and (C) patients with ALL. Values are the means ± SD. Estimated radiation absorbed doses to marrow were calculated using published methods.4142 Recently proposed marrow S values incorporated in MIRDOSE3 software60 would result in lower marrow doses than noted here. AML–Remission group includes a patient in marrow remission with leukemia cutis. *P = .04 for difference between marrow remission and relapse in patients with AML/MDS; **P = .001 for difference between marrow remission and relapse in patients with AML/MDS.

Estimated radiation absorbed doses per millicurie of131I administered for (A) all patients, (B) patients with AML or MDS, and (C) patients with ALL. Values are the means ± SD. Estimated radiation absorbed doses to marrow were calculated using published methods.41,42 Recently proposed marrow S values incorporated in MIRDOSE3 software60 would result in lower marrow doses than noted here. AML–Remission group includes a patient in marrow remission with leukemia cutis. *P = .04 for difference between marrow remission and relapse in patients with AML/MDS; **P = .001 for difference between marrow remission and relapse in patients with AML/MDS.

Close Modal

or Create an Account

Close Modal
Close Modal